NEXLETOL (bempedoic acid)
ANTIHYPERLIPIDEMIC - ATP-CITRATE LYASE (ACLY) INHIBITOR · HYPERLIPIDEMIA ·+2
ESPERION THERAP
Drug class
Antihyperlipidemic - ATP-Citrate Lyase (ACLY) Inhibitor
The class "Antihyperlipidemic - ATP-Citrate Lyase (ACLY) Inhibitor" is a standard formulary and compendia classification representing non-statin oral lipid-lowering agents, primarily exemplified by bempedoic acid. Read more about Antihyperlipidemic - ATP-Citrate Lyase (ACLY) Inhibitor
2 drugs in this class 1 manufacturers
Drugs in Antihyperlipidemic - ATP-Citrate Lyase (ACLY) Inhibitor
NEXLIZET (bempedoic acid/ezetimibe)
SELECTIVE CHOLESTEROL ABSORPTION INHIBITOR · HYPERLIPIDEMIA ·+2
ESPERION THERAP
Filter & compare in the drug finder →
Opens the drug finder with Antihyperlipidemic - ATP-Citrate Lyase (ACLY) Inhibitor preselected. Add indication or manufacturer filters there.
The class "Antihyperlipidemic - ATP-Citrate Lyase (ACLY) Inhibitor" is a standard formulary and compendia classification representing non-statin oral lipid-lowering agents, primarily exemplified by bempedoic acid.
These agents act as prodrugs that are converted into an active metabolite within hepatocytes to inhibit ATP-citrate lyase, an enzyme operating upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway.
This inhibition reduces hepatic cholesterol synthesis and upregulates low-density lipoprotein (LDL) receptors, facilitating increased clearance of circulating LDL cholesterol.
The class is therapeutically indicated as an adjunct to diet and maximally tolerated lipid-lowering therapy to reduce LDL-C and lower cardiovascular risk in adults with primary hyperlipidemia, heterozygous familial hypercholesterolemia, or established atherosclerotic cardiovascular disease.
-
iehp.org
The class "Antihyperlipidemic - ATP-Citrate Lyase (ACLY) Inhibitor" is a standard formulary and compendia classification representing non-statin oral lipid-lowering agents, primarily exemplified by bempedoic acid
-
wellfleetrx.com
The class "Antihyperlipidemic - ATP-Citrate Lyase (ACLY) Inhibitor" is a standard formulary and compendia classification representing non-statin oral lipid-lowering agents, primarily exemplified by bempedoic acid
-
fda.gov
These agents act as prodrugs that are converted into an active metabolite within hepatocytes to inhibit ATP-citrate lyase, an enzyme operating upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway
-
fda.gov
The class is therapeutically indicated as an adjunct to diet and maximally tolerated lipid-lowering therapy to reduce LDL-C and lower cardiovascular risk in adults with primary hyperlipidemia, heterozygous familial hypercholesterolemia, or established atherosclerotic cardiovascular disease
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.